Skip to main content
Caplight Logo









Mirror Biologics, Inc.

Mirror Biologics, Inc.

Private
Tampa, FloridaHealthcare & Life Scienceshttp://www.mirrorbiologics.com/

Last Round

Series A

Oct 11, 2022

Total Funding Raised

$30M

Company Overview

Mirror Biologics, Inc. is a biotechnology company that develops and manufactures off-the-shelf, living immune cell immunotherapies for the treatment of metastatic cancer and infectious diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

immunotherapyallogeneic cell therapyAllo-APCToff-the-shelf cell therapyoff-the-shelf immunotherapyGMP contract manufacturingCDMOoncology therapeuticsbiotechnologyinfectious disease treatmentcell therapy manufacturingbiological therapeuticsclinical-stage biotechcell therapy scale-uptechnology transfer

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Mirror Biologics, Inc. Comparables

Compare Mirror Biologics, Inc. with similar companies based on industry and business-model similarity.

Mirror Biologics, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Sana Biotechnology
74%
Artiva
73%
Atara Biotherapeutics
73%

Mirror Biologics, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AOct 11, 2022

Key People

Founding team and executive leadership

Elizabeth Adkins Czerepak

CFO (April 2024-Present) Acting CEO (July 2024-May 2025)

Executive Team

Mirror Biologics, Inc. Investors

Notable investors and investment history

Mirror Biologics, Inc. investors
InvestorRounds
Bradbury Asset Management (Hong Kong) LimitedSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 13, 2024

    Grew 16% QoQ, from 19 to 22 employees.

  • Jul 9, 2024

    Grew 18% QoQ, from 17 to 20 employees.

Mirror Biologics, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Mirror Biologics, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Mirror Biologics, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersTampa, Florida
Employee Range17
Year Founded2019
Last FundingOct 11, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?